查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1387501

Omega-3處方藥市場報告：2030 年趨勢、預測與競爭分析

Omega 3 Prescription Drug Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

Omega-3處方藥趨勢與預測

到 2030 年，全球Omega-3處方藥市場預計將達到 48 億美元，2024 年至 2030 年年複合成長率為 8.5%。這個市場的主要促進因素是高三酸甘油脂血症、肥胖、心血管疾病 (CVD)比例的上升，以及人們對維持膽固醇水平的意識不斷增強，市場參與者希望治療相關的醫療問題。我們專注於創造創新藥物。全球Omega-3處方藥市場的未來前景廣闊，高三酸甘油脂血症、高高膽固醇症發炎性腸道疾病、發炎性腸道疾病、類風濕性關節炎、精神疾病和神經發育障礙市場存在機會。

Omega-3處方藥市場洞察

Lucintel 預測，由於 Vascepa 的廣泛接受度，在預測期內仍將是最大的細分市場。

由於該地區對心臟相關疾病的擔憂不斷增加，預計北美在預測期內仍將是最大的地區。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和業務風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球Omega-3處方藥市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球Omega-3處方藥市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥品分類的全球Omega-3處方藥市場
    • Vascepa
    • Lovaza
    • 其他
  • 按配銷通路的全球Omega-3處方藥市場
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 全球Omega-3處方藥市場（按應用）
    • 高三酸甘油脂血症
    • 高膽固醇
    • 發炎性腸道疾病
    • 類風濕性關節炎
    • 精神疾病
    • 神經發育障礙
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球Omega-3處方藥市場（按地區）
  • 北美Omega-3處方藥市場
  • 歐洲Omega-3處方藥市場
  • 亞太地區Omega-3處方藥市場
  • 其他地區Omega-3處方藥市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球Omega-3處方藥市場成長機會（依藥品分類）
    • 全球Omega-3處方藥市場成長機會（依配銷通路）
    • 全球Omega-3處方藥市場成長機會（按應用）
    • 全球Omega-3處方藥市場成長機會（按地區）
  • 全球Omega-3處方藥市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球Omega-3處方藥市場產能
    • 全球Omega-3處方藥市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Abbott
  • Amarin Pharmaceuticals
  • GSK
  • Natrapharm
  • Viatris
  • Grupo Ferrer Internacional
  • Camber Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Zydus
  • Hikma Pharmaceuticals
簡介目錄

Omega 3 Prescription Drug Trends and Forecast

The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets. The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030 with a CAGR of 8.5% from 2024 to 2030. The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

A more than 150-page report is developed to help in your business decisions.

Omega 3 Prescription Drug by Segment

The study includes a forecast for the global omega 3 prescription drug by drug, distribution channel, application, and region.

Omega 3 Prescription Drug Market by Drug [Shipment Analysis by Value from 2018 to 2030]:

  • Vascepa
  • Lovaza
  • Others

Omega 3 Prescription Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Omega 3 Prescription Drug Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypertriglyceridemia
  • High Cholesterol
  • Inflammatory Bowel Disease
  • Rheumatoid Arthritis
  • Mental Health Conditions
  • Neurodevelopmental Disorders
  • Others

Omega 3 Prescription Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Omega 3 Prescription Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies omega 3 prescription drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the omega 3 prescription drug companies profiled in this report include-

  • Abbott
  • Amarin Pharmaceuticals
  • GSK
  • Natrapharm
  • Viatris
  • Grupo Ferrer Internacional
  • Camber Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Zydus
  • Hikma Pharmaceuticals

Omega 3 Prescription Drug Market Insights

Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Features of the Global Omega 3 Prescription Drug Market

Market Size Estimates: Omega 3 prescription drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Omega 3 prescription drug market size by drug, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Omega 3 prescription drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug, distribution channel, application, and regions for the omega 3 prescription drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the omega 3 prescription drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the omega 3 prescription drug market size?

Answer: The global omega 3 prescription drug market is expected to reach an estimated $4.8 billion by 2030.

Q2. What is the growth forecast for omega 3 prescription drug market?

Answer: The global omega 3 prescription drug market is expected to grow with a CAGR of 8.5% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the omega 3 prescription drug market?

Answer: The major drivers for this market are rising rates of hypertriglyceridemia, obesity, and cardiovascular diseases (CVDs), growing awareness for maintaining cholesterol levels, and players in the market are concentrating on creating innovative medications to treat linked medical issues.

Q4. What are the major segments for omega 3 prescription drug market?

Answer: The future of the global omega 3 prescription drug market looks promising with opportunities in the hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders markets.

Q5. Who are the key omega 3 prescription drug market companies?

Answer: Some of the key omega 3 prescription drug companies are as follows:

  • Abbott
  • Amarin Pharmaceuticals
  • GSK
  • Natrapharm
  • Viatris
  • Grupo Ferrer Internacional
  • Camber Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Zydus
  • Hikma Pharmaceuticals

Q6. Which omega 3 prescription drug market segment will be the largest in future?

Answer: Lucintel forecasts that vascepa will remain the largest segment over the forecast period due to widespread acceptance of vascepa.

Q7. In omega 3 prescription drug market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing regional apprehension regarding heart-related conditions.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the omega 3 prescription drug market by drug (vascepa, lovaza, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), application (hypertriglyceridemia, high cholesterol, inflammatory bowel disease, rheumatoid arthritis, mental health conditions, neurodevelopmental disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Omega 3 Prescription Drug Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Omega 3 Prescription Drug Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Omega 3 Prescription Drug Market by Drug
    • 3.3.1: Vascepa
    • 3.3.2: Lovaza
    • 3.3.3: Others
  • 3.4: Global Omega 3 Prescription Drug Market by Distribution Channel
    • 3.4.1: Hospital Pharmacy
    • 3.4.2: Retail Pharmacy
    • 3.4.3: Online Pharmacy
  • 3.5: Global Omega 3 Prescription Drug Market by Application
    • 3.5.1: Hypertriglyceridemia
    • 3.5.2: High Cholesterol
    • 3.5.3: Inflammatory Bowel Disease
    • 3.5.4: Rheumatoid Arthritis
    • 3.5.5: Mental Health Conditions
    • 3.5.6: Neurodevelopmental Disorders
    • 3.5.7: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Omega 3 Prescription Drug Market by Region
  • 4.2: North American Omega 3 Prescription Drug Market
    • 4.2.2: North American Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
  • 4.3: European Omega 3 Prescription Drug Market
    • 4.3.1: European Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
    • 4.3.2: European Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
  • 4.4: APAC Omega 3 Prescription Drug Market
    • 4.4.1: APAC Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
    • 4.4.2: APAC Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others
  • 4.5: ROW Omega 3 Prescription Drug Market
    • 4.5.1: ROW Omega 3 Prescription Drug Market by Drug: Vascepa, Lovaza, and Others
    • 4.5.2: ROW Omega 3 Prescription Drug Market by Application: Hypertriglyceridemia, High Cholesterol, Inflammatory Bowel Disease, Rheumatoid Arthritis, Mental Health Conditions, Neurodevelopmental Disorders, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Drug
    • 6.1.2: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Application
    • 6.1.4: Growth Opportunities for the Global Omega 3 Prescription Drug Market by Region
  • 6.2: Emerging Trends in the Global Omega 3 Prescription Drug Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Omega 3 Prescription Drug Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Omega 3 Prescription Drug Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Abbott
  • 7.2: Amarin Pharmaceuticals
  • 7.3: GSK
  • 7.4: Natrapharm
  • 7.5: Viatris
  • 7.6: Grupo Ferrer Internacional
  • 7.7: Camber Pharmaceuticals
  • 7.8: Dr. Reddy's Laboratories
  • 7.9: Zydus
  • 7.10: Hikma Pharmaceuticals